| Drug Name | Adakveo® (crizanlizumab) |
|---|---|
| Drug Class | |
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Hematology
|
| Risk |
Phase III study (CSEG101A2301) shows no superiority of crizanlizumab over placebo |
| Dear Healthcare provider letter DHPC |
|